New, expanded, and modified use of approved antineoplastic agents in ovarian cancer

Oncologist

Volumn 12, Issue 2, 2007, Pages 186-190

  Markman, Maurie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer chemotherapy; Combination chemotherapy; Ovarian cancer; Second line chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER ANTIBODY; CANFOSFAMIDE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE ANTIBODY; ETOPOSIDE; GEMCITABINE; IRINOTECAN; MONOCLONAL ANTIBODY CD3; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TOPOTECAN; TRABECTEDIN; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOTOXICITY TEST; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; FOOD AND DRUG ADMINISTRATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MONOTHERAPY; MUCOSA INFLAMMATION; NEUROPATHY; ONCOLOGY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; SOFT TISSUE SARCOMA; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 33847058847     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-2-186     Document Type: Review

References (47)

1. Alberts DS, Green S, Hannigan EV et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992;10:706-717.
2. Swenerton K, Jeffrey J, Stuart G et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992;10:718-726.
3. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
4. Thigpen JT, Blessing JA, Ball H et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 1994;12:1748-1753.
5. Markman M, Hall J, Spitz D et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 2002;20:2365-2369.
6. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study. Gynecol Oncol 2006;101:436-440.
7. Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460-2465.
8. Armstrong DK, Bundy B, Wenzel L et al. Phase III randomized trial of intravenous cisplatin and paclitaxel versus an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin and intraperitoneal paclitaxel in stage III ovarian cancer: A Gynecologic Oncology Group Study. N Engl J Med 2006;354:34-43.
9. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-2106.
10. Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96:1682-1691.
11. Verschraegen CF, Sittisomwong T, Kudelka AP et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 2000;18:2733-2739.
12. Rose PG, Blessing JA, Ball HG et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2003;88:130-135.
13. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-1955.
14. Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-1007.
15. Shapiro JD, Millward MJ, Rischin D et al. Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 1996;63:89-93.
16. D'Agostino G, Amant F, Berteloot P et al. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol 2003;88:266-269.
17. Pfisterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin vs. carboplatin in platinum sensitive recurrent ovarian cancer: Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2004;22(suppl):450s.
18. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-2193.
19. Creemers GJ, Bolis G, Gore M et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 1996;14:3056-3061.
20. McGuire WP, Blessing JA, Bookman MA et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2000;18:1062-1067.
21. Gronlund B, Hansen HH, Hogdall C et al. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. Cancer 2002;95:1656-1662.
22. Rodriguez M, Rose PG. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol 2001;83:257-262.
23. Mitchell SK, Carson LF, Judson P et al. Efficacy and tolerability of lower-dose topotecan in recurrent ovarian cancer: A retrospective case review. Int J Gynecol Cancer 2005;15:793-798.
24. Brown JV 3rd, Peters WA 3rd, Rettenmaier MA et al. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol Oncol 2003;88:136-140.
25. Miller DS, Blessing JA, Lentz SS et al. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study. Cancer 2003;98:1664-1669.
26. Bhoola SM, Coleman RL, Herzog T et al. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol 2004;95:564-569.
27. Levy T, Inbar M, Menczer J et al. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol 2004;95:686-690.
28. O'Malley DM, Azodi M, Makkenchery A et al. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2005;98:242-248.
29. Gordon AN, Granai CO, Rose PG et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000;18:3093-3100.
30. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-3322.
31. Campos SM, Penson RT, Mays AR et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 2001;81:206-212.
32. 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 2000;78:369-372.
33. Rose PG, Maxson JH, Fusco N et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: A retrospective comparative study of single-agent dosages. Gynecol Oncol 2001;82:323-328.
34. Thigpen JT, Aghajanian CA, Alberts DS et al. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 2005;96:10-18.
35. Monk BJ, Choi DC, Pugmire G et al. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2005;96:902-905.
36. Wright JD, Hagemann A, Rader JS et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer 2006;107:83-89.
37. Burger RA, Sill M, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol 2005;23(suppl):457s.
38. Cannistra SA, Matulonis U, Penson R et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J Clin Oncol 2006;24(suppl):257s.
39. Bodurka DC, Levenback C, Wolf JK et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 2003;21:291-297.
40. Gershenson DM, Burke TW, Morris M et al. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol Oncol 1998;70:404-409.
41. Sorensen P, Hoyer M, Jakobsen A et al. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol 2001;81:58-62.
42. Bajetta E, Di Leo A, Biganzoli L et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 1996;14:2546-2551.
43. Rose PG, Blessing JA, Mayer AR et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1998;16:405-410.
44. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994;12:60-63.
45. Milano A, Apice G, Ferrari E et al. New emerging drugs in soft tissue sarcoma. Crit Rev Oncol/Hematol 2006;59:74-84.
46. Sessa C, De Braud F, Perotti A et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005;23:1867-1874.
47. Kavanagh JJ, Gershenson DM, Choi H et al. Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int J Gynecol Oncol 2005;15:593-600.